RCT: Single-Dose Johnson & Johnson Vaccine has 85% efficacy against severe/critical Covid-19 and maintains efficacy against variant B.1.351
Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19 – New England Journal of Medicine
The post RCT: Single-Dose Johnson & Johnson Vaccine has 85% efficacy against severe/critical Covid-19 and maintains efficacy against variant B.1.351 appeared first on Links Medicus.
-
Taille de police
Réduire la taille de la police
Augmenter la taille de police
About Author
Dernier de Zouhair Souissi
- Non-inferiority RCT: Reduced-Dose vs Full-Dose Direct Oral Anticoagulants for Extended VTE Treatment
- Systematic Review: Shorter Antibiotic Courses Often Prove Non-Inferior for Common Bacterial Infections
- Network Meta-analysis: Oseltamivir Fails to Improve Key Outcomes in Nonsevere Influenza
- Multidrug-resistant Gram-negative bacterial infections: Key Updates and Practical Strategies
- Introducing Our Free WhatsApp Channels for Daily Internal Medicine Articles!